Media stories about Nevro (NYSE:NVRO) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nevro earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.8806315745125 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
Nevro (NYSE NVRO) opened at $78.56 on Friday. Nevro has a 12 month low of $65.00 and a 12 month high of $99.63. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.81 and a current ratio of 8.78.
Nevro (NYSE:NVRO) last announced its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. The company had revenue of $82.26 million during the quarter, compared to analysts’ expectations of $80.50 million. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. Nevro’s quarterly revenue was up 35.0% on a year-over-year basis. During the same period last year, the business earned ($0.14) earnings per share. equities research analysts anticipate that Nevro will post -1.27 EPS for the current fiscal year.
Several research firms recently weighed in on NVRO. Zacks Investment Research lowered Nevro from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Canaccord Genuity reiterated a “buy” rating and issued a $120.00 target price on shares of Nevro in a research note on Sunday, October 8th. BidaskClub upgraded Nevro from a “sell” rating to a “hold” rating in a research note on Saturday, October 7th. Northland Securities reissued a “buy” rating and set a $96.00 price target on shares of Nevro in a research report on Tuesday, November 7th. Finally, Leerink Swann reissued an “outperform” rating and set a $110.00 price target (up previously from $105.00) on shares of Nevro in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Nevro currently has an average rating of “Hold” and a consensus price target of $99.25.
In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.10% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/nevro-nvro-receives-news-sentiment-score-of-0-14.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.